journal
https://read.qxmd.com/read/38761791/oncological-outcomes-of-local-excision-versus-radical-surgery-for-early-rectal-cancer-in-the-context-of-staging-and-surveillance-a-systematic-review-and-meta-analysis
#1
REVIEW
Michael G Fadel, Mosab Ahmed, Annabel Shaw, Matyas Fehervari, Christos Kontovounisios, Gina Brown
BACKGROUND: Local resection (LR) methods for rectal cancer are generally considered in the palliative setting or for patients deemed a high anaesthetic risk. This systematic review and meta-analysis aimed to compare oncological outcomes of LR and radical resection (RR) for early rectal cancer in the context of staging and surveillance assessment. METHODS: A literature search of MEDLINE, Embase and Emcare databases was performed for studies that reported data on clinical outcomes for both LR and RR for early rectal cancer from January 1995 to April 2023...
May 12, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38729086/toxicity-of-immunotherapy-combinations-with-chemotherapy-across-tumor-indications-current-knowledge-and-practical-recommendations
#2
REVIEW
Layal Rached, Ariane Laparra, Madona Sakkal, François-Xavier Danlos, Fabrice Barlesi, Franck Carbonnel, Eleonora De Martin, Michel Ducreux, Caroline Even, Jerome Le Pavec, Jean-Marie Michot, Joana M Ribeiro, Florian Scotte, Santiago Ponce Aix, Olivier Lambotte, Capucine Baldini, Stéphane Champiat
Chemotherapy associated with Immune Checkpoint Inhibitors is currently the standard of care in several tumor indications. This combination approach improves progression free survival (PFS), overall survival (OS) and complete pathological response (pCR) in several cancer types both in the early and metastatic approaches. However, the distinct spectrum of toxicities between cytotoxic side effects and immune related adverse events (irAEs) with similar clinical presentations and different management strategies remains a challenge in daily practice for healthcare professionals...
May 4, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38703592/neoadjuvant-management-of-locally-advanced-pancreatic-ductal-adenocarcinoma-heading-towards-a-promising-change-in-treatment-paradigm
#3
REVIEW
Umair Mahmood, Ewa Carrier, Khurum Khan
Traditional chemotherapy-based adjuvant therapies for locally advanced pancreatic ductal adenocarcinoma (PDAC) have been associated with poor clinical outcomes driven partly by its complex anatomy and molecular heterogeneity. Treatment for PDAC is challenged by presence of a dense tumour microenvironment involving an interplay of multiple tumoural and stromal components which promote metastatic oncogenic behaviour. PDAC also involves aberrations in multiple signalling pathways with paucity of treatment options against the most common mutations including KRAS, TP53, CDKN2A andSMAD4...
May 3, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38714074/havoc-in-harmony-unravelling-the-intricacies-of-angiogenesis-orchestrated-by-the-tumor-microenvironment
#4
REVIEW
Sushree Subhadra Acharya, Chanakya Nath Kundu
Cancer cells merely exist in isolation; rather, they exist in an intricate microenvironment composed of blood vessels, signalling molecules, immune cells, stroma, fibroblasts, and the ECM. The TME provides a setting that is favourable for the successful growth and survivance of tumors. Angiogenesis is a multifaceted process that is essential for the growth, invasion, and metastasis of tumors. TME can be visualized as a "concert hall," where various cellular and non-cellular factors perform in a "symphony" to orchestrate tumor angiogenesis and create "Havoc" instead of "Harmony"...
May 1, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38703593/salivary-toxicity-from-psma-targeted-radiopharmaceuticals-what-we-have-learned-and-where-we-are-going
#5
REVIEW
Miguel Muniz, Charles L Loprinzi, Jacob J Orme, Regina M Koch, Ahmed M Mahmoud, Adam M Kase, Irbaz B Riaz, Jack R Andrews, Matthew P Thorpe, Geoffrey B Johnson, Ayse T Kendi, Eugene D Kwon, Jones T Nauseef, Alicia K Morgans, Oliver Sartor, Daniel S Childs
Clinical trials of prostate-specific membrane antigen (PSMA) targeted radiopharmaceuticals have shown encouraging results. Some agents, like lutetium-177 [177Lu]Lu-PSMA-617 ([177 Lu]Lu-PSMA-617), are already approved for late line treatment of metastatic castration-resistant prostate cancer (mCRPC). Projections are for continued growth of this treatment modality; [177 Lu]Lu-PSMA-617 is being studied both in earlier stages of disease and in combination with other anti-cancer therapies. Further, the drug development pipeline is deep with variations of PSMA-targeting radionuclides, including higher energy alpha particles conjugated to PSMA-honing vectors...
April 30, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38723394/treatment-options-in-first-line-metastatic-renal-carcinoma-a-meta-analysis-of-2556-patients-treated-with-immune-checkpoint-inhibitors-based-combinations-in-randomised-controlled-trials
#6
REVIEW
Marcello Tucci, Marta Mandarà, Jacopo Giuliani, Emilia Durante, Consuelo Buttigliero, Fabio Turco, Erica Palesandro, Ilaria Campisi, Navdeep Singh, Marco Muraro, Fernando Munoz, Francesco Fiorica
BACKGROUND & AIMS: The average five-year survival of metastatic renal cell carcinoma (mRCC) is 71%. However, there is significant variability in patient prognosis. Immune checkpoint inhibitors (ICIs) have been introduced into the treatment landscape of mRCC. This meta-analysis aimed to estimate progression-free and overall survival probabilities and identify possible outcome predictors of mRCC patients treated with ICI combination as first-line treatment. METHODS: Studies comparing the combination of ICI combinations versus standard of therapy for first-line treatment of advanced renal-cell carcinoma were searched in MEDLINE, CANCERLIT, the Cochrane Controlled Trials Register, and the Cochrane Library from inception through September 2023...
April 27, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38696902/intratumoral-therapies-in-head-and-neck-squamous-cell-carcinoma-a-systematic-review-and-future-perspectives
#7
REVIEW
Pablo Jiménez-Labaig, Antonio Rullan, Irene Braña, Alberto Hernando-Calvo, Victor Moreno, Bernard Doger, George Bitar, Derfel Ap Dafydd, Alan Melcher, Kevin J Harrington
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) presents an ideal scenario for intratumoral therapies (IT), due to its local recurrence pattern and frequent superficial extension. IT therapies aim to effect tumor regression by directly injecting antineoplastic agents into lesions. However, there is a lack of updated evidence regarding IT therapies in HNSCC. PATIENTS AND METHODS: A systematic literature search (CRD42023462291) was conducted using WebOfScience, ClinicalTrials...
April 27, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38678643/corrigendum-to-pharmacological-prevention-and-treatment-of-opioid-induced-constipation-in-cancer-patients-a-systematic-review-and-meta-analysis-cancer-treat-rev-125-2024-102704
#8
K R J Kistemaker, F Sijani, D J Brinkman, A de Graeff, G L Burchell, M A H Steegers, L van Zuylen
No abstract text is available yet for this article.
April 27, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38669788/the-tumor-immune-composition-of-mismatch-repair-deficient-and-epstein-barr-virus-positive-gastric-cancer-a-systematic-review
#9
REVIEW
J Bos, T S Groen-van Schooten, C P Brugman, F S Jamaludin, H W M van Laarhoven, S Derks
BACKGROUND: Gastric cancer (GC), known for its unfavorable prognosis, has been classified in four distinct molecular subtypes. These subtypes not only exhibit differences in their genome and transcriptome but also in the composition of their tumor immune microenvironment. The microsatellite instable (MSI) and Epstein-Barr virus (EBV) positive GC subtypes show clear clinical benefits from immune checkpoint blockade, likely due to a neoantigen-driven and virus-driven antitumor immune response and high expression of immune checkpoint molecule PD-L1...
April 20, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38696903/dutch-national-guidelines-for-locally-recurrent-rectal-cancer
#10
REVIEW
Floor Piqeur, Davy M J Creemers, Evi Banken, Liën Coolen, Pieter J Tanis, Monique Maas, Mark Roef, Corrie A M Marijnen, Irene E G van Hellemond, Joost Nederend, Harm J T Rutten, Heike M U Peulen, Jacobus W A Burger
Due to improvements in treatment for primary rectal cancer, the incidence of LRRC has decreased. However, 6-12% of patients will still develop a local recurrence. Treatment of patients with LRRC can be challenging, because of complex and heterogeneous disease presentation and scarce - often low-grade - data steering clinical decisions. Previous consensus guidelines have provided some direction regarding diagnosis and treatment, but no comprehensive guidelines encompassing all aspects of the clinical management of patients with LRRC are available to date...
April 19, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38733648/ntrk-gene-fusion-testing-and-management-in-lung-cancer
#11
REVIEW
Matteo Repetto, Marina Chiara Garassino, Herbert H Loong, Fernando Lopez-Rios, Tony Mok, Solange Peters, David Planchard, Sanjay Popat, Erin R Rudzinski, Alexander Drilon, Caicun Zhou
Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are recurrent oncogenic drivers found in a variety of solid tumours, including lung cancer. Several tropomyosin receptor kinase (TRK) inhibitors have been developed to treat tumours with NTRK gene fusions. Larotrectinib and entrectinib are first-generation TRK inhibitors that have demonstrated efficacy in patients with TRK fusion lung cancers. Genomic testing is recommended for all patients with metastatic non-small cell lung cancer for optimal drug therapy selection...
April 3, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38493647/corrigendum-to-breaking-barriers-in-triple-negative-breast-cancer-tnbc-unleashing-the-power-of-antibody-drug-conjugates-adcs-cancer-treatment-reviews-123-2024-102672
#12
Arianna Dri, Grazia Arpino, Giampaolo Bianchini, Giuseppe Curigliano, Romano Danesi, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Alessandra Gennari, Valentina Guarneri, Daniele Santini, Edda Simoncini, Claudio Zamagni, Fabio Puglisi
No abstract text is available yet for this article.
March 16, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38502995/clinical-management-monitoring-and-prophylaxis-of-adverse-events-of-special-interest-associated-with-datopotamab-deruxtecan
#13
REVIEW
Rebecca S Heist, Jacob Sands, Aditya Bardia, Toshio Shimizu, Aaron Lisberg, Ian Krop, Noboru Yamamoto, Takahiro Kogawa, Saba Al-Hashimi, Simon S M Fung, Anat Galor, Francesca Pisetzky, Priyanka Basak, Cindy Lau, Funda Meric-Bernstam
Antibody drug conjugates (ADCs) are an emerging class of treatments designed to improve efficacy and decrease toxicity compared with other systemic therapies through the selective delivery of cytotoxic agents to tumor cells. Datopotamab deruxtecan (Dato-DXd) is a novel ADC comprising a topoisomerase I inhibitor payload and a monoclonal antibody directed to trophoblast cell-surface antigen 2 (TROP2), a protein that is broadly expressed in several types of solid tumors. Dato-DXd is being investigated across multiple solid tumor indications...
March 11, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38484408/tumor-agnostic-baskets-to-n-of-1-platform-trials-and-real-world-data-transforming-precision-oncology-clinical-trial-design
#14
REVIEW
Elena Fountzilas, Apostolia-Maria Tsimberidou, Henry Hiep Vo, Razelle Kurzrock
Choosing the right drug(s) for the right patient via advanced genomic sequencing and multi-omic interrogation is the sine qua non of precision cancer medicine. Traditional cancer clinical trial designs follow well-defined protocols to evaluate the efficacy of new therapies in patient groups, usually identified by their histology/tissue of origin of their malignancy. In contrast, precision medicine seeks to optimize benefit in individual patients, i.e., to define who benefits rather than determine whether the overall group benefits...
March 4, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38636443/neoadjuvant-egfr-tki-therapy-in-non-small-cell-lung-cancer
#15
REVIEW
Christopher Grant, Misako Nagasaka
Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with EGFR and ALK alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with EGFR-TKI monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials' potential benefits, challenges, and future directions in the field...
May 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38613872/first-line-combination-treatment-with-parp-and-androgen-receptor-signaling-inhibitors-in-hrr-deficient-mcrpc-applying-clinical-study-findings-to-clinical-practice-in-the-united-states
#16
REVIEW
Rana R McKay, Alicia K Morgans, Neal D Shore, Curtis Dunshee, Geeta Devgan, Neeraj Agarwal
INTRODUCTION: Metastatic castration-resistant prostate cancer (mCRPC) remains incurable and develops from biochemically recurrent PC treated with androgen deprivation therapy (ADT) following definitive therapy for localized PC, or from metastatic castration-sensitive PC (mCSPC). In the mCSPC setting, treatment intensification of ADT plus androgen receptor (AR)-signaling inhibitors (ARSIs), with or without chemotherapy, improves outcomes vs ADT alone. Despite multiple phase 3 trials demonstrating a survival benefit of treatment intensification in PC, there remains high use of ADT monotherapy in real-world clinical practice...
May 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38613871/waiting-for-the-liquid-revolution-in-the-adjuvant-treatment-of-colon-cancer-patients-a-review-of-ongoing-trials
#17
REVIEW
V Conca, P Ciracì, C Boccaccio, A Minelli, C Antoniotti, C Cremolini
Since colon cancer has a high rate of shedding of tumour fragments into the blood, several research efforts are now focused on the investigation of the minimal residual disease through the detection of ctDNA to tailor the adjuvant therapy of colon cancer patients and optimize its cost/effectiveness balance. The negative prognostic impact of detectable ctDNA in patients' blood after radical surgery for colon cancer is well established. Several clinical trials adopting heterogeneous designs and techniques are now ongoing to translate promises into daily practice by answering five general questions: i) is a ctDNA-guided decision making efficacious in the post-operative management of colon cancer patients? ii) are de-escalation strategies possible in ctDNA-negative cases? iii) are escalation strategies useful to improve the prognosis of ctDNA-positive patients? iv) when MRD is identified at the end of the adjuvant chemotherapy, is another post-adjuvant systemic therapy efficacious? v) can we exploit ctDNA technologies in the follow up of colon cancer patients? This review focuses on currently ongoing trials and how their results may affect the ctDNA "liquid revolution" of early colon cancer...
May 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38604052/clinical-recommendations-for-treatment-of-localized-angiosarcoma-a-consensus-paper-by-the-italian-sarcoma-group
#18
REVIEW
Elena Palassini, Giacomo Giulio Baldi, Sara Sulfaro, Marta Barisella, Giuseppe Bianchi, Domenico Campanacci, Marco Fiore, Marco Gambarotti, Massimiliano Gennaro, Carlo Morosi, Federico Navarria, Emanuela Palmerini, Claudia Sangalli, Marta Sbaraglia, Annalisa Trama, Sebastian Asaftei, Giuseppe Badalamenti, Rossella Bertulli, Alexia Francesca Bertuzzi, Roberto Biagini, Angela Bonadonna, Antonella Brunello, Dario Callegaro, Ferdinando Cananzi, Marco Cianchetti, Paola Collini, Danila Comandini, Annalisa Curcio, Lorenzo D'Ambrosio, Tommaso De Pas, Angelo Paolo Dei Tos, Virginia Ferraresi, Andrea Ferrari, Alessandro Franchi, Anna Maria Frezza, Elena Fumagalli, Matteo Ghilli, Daniela Greto, Giovanni Grignani, Michele Guida, Toni Ibrahim, Marco Krengli, Roberto Luksch, Andrea Marrari, Marinella Mastore, Alessandra Merlini, Giuseppe Maria Milano, Piera Navarria, Maria Abbondanza Pantaleo, Antonina Parafioriti, Ilaria Pellegrini, Elisabetta Pennacchioli, Marco Rastrelli, Elisabetta Setola, Salvatore Tafuto, Salvatore Turano, Sergio Valeri, Bruno Vincenzi, Viviana Vitolo, Andrei Ivanescu, Fiammetta Paloschi, Paolo Giovanni Casali, Alessandro Gronchi, Silvia Stacchiotti
Angiosarcoma (AS) represents a rare and aggressive vascular sarcoma, posing distinct challenges in clinical management compared to other sarcomas. While the current European Society of Medical Oncology (ESMO) clinical practice guidelines for sarcoma treatment are applicable to AS, its unique aggressiveness and diverse tumor presentations necessitate dedicated and detailed clinical recommendations, which are currently lacking. Notably, considerations regarding surgical extent, radiation therapy (RT), and neoadjuvant/adjuvant chemotherapy vary significantly in localized disease, depending on each different site of onset...
May 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38604051/endocrine-metabolic-assessment-checklist-for-cancer-patients-treated-with-immunotherapy-a-proposal-by-the-italian-association-of-medical-oncology-aiom-italian-association-of-medical-diabetologists-amd-italian-society-of-diabetology-sid-italian-society-of-endocrinology
#19
REVIEW
Maria Chiara Zatelli, Antongiulio Faggiano, Antonella Argentiero, Romano Danesi, Stella D'Oronzo, Stefano Fogli, Tindara Franchina, Francesco Giorgino, Nicola Marrano, Dario Giuffrida, Stefania Gori, Giampiero Marino, Rossella Mazzilli, Matteo Monami, Monica Montagnani, Lelio Morviducci, Annalisa Natalicchio, Alberto Ragni, Valerio Renzelli, Antonio Russo, Laura Sciacca, Enzo Tuveri, Gianluca Aimaretti, Angelo Avogaro, Riccardo Candido, Massimo Di Maio, Nicola Silvestris, Marco Gallo
Immunotherapy with immune checkpoint inhibitors (ICI) is increasingly employed in oncology. National and international endocrine and oncologic scientific societies have provided guidelines for the management of endocrine immune-related adverse events. However, guidelines recommendations differ according to the specific filed, particularly pertaining to recommendations for the timing of endocrine testing. In this position paper, a panel of experts of the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), and Italian Society of Pharmacology (SIF) offers a critical multidisciplinary consensus for a clear, simple, useful, and easily applicable endocrine-metabolic assessment checklist for cancer patients on immunotherapy...
May 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38574507/intermittent-fasting-and-its-impact-on-toxicities-symptoms-and-quality-of-life-in-patients-on-active-cancer-treatment
#20
REVIEW
Robert Li Sucholeiki, Casey L Propst, David S Hong, Goldy C George
Intermittent fasting is a dietary intervention that is increasingly being tested for positive outcomes in patients receiving cancer treatment. In this review, we examine the impact of intermittent fasting on symptoms, toxicities, and quality of life in patients undergoing cancer therapy and highlight unmet investigative areas to prompt future research. While current evidence is preliminary and conclusions mixed, some promising clinical studies suggest that intermittent fasting interventions may improve fatigue and reduce gastrointestinal toxicities in certain patients with cancer...
May 2024: Cancer Treatment Reviews
journal
journal
25655
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.